…ical pharmacology sections of the application were insufficient to allow a complete review. Celgene will meet with FDA officials to discuss what additional information is needed, but the setback is expected to significantly delay the launch of ozanimod. The drug was expected to obtain approval in late 2018/early 2019, but that will likely be delayed at least 9-12 months. As a result, ozanimod is now expected to be launched in the U.S. after generi…

…and resources to MS patients, and attracts about 35,000 visitors per year (www.msology.com). The 21-item survey asked patients currently treated with DMF about their experiences with the drug. All of the Canadian respondents (n=48) were current or recent DMF users. A majority of respondents were female (96%), aged 41 years or older (81%). Forty-percent were previously untreated, and 60% had been on a prior injectable DMT. Most had been taking DMF…

…018; epublished January 1, 2018; free full text at http://journals.sagepub.com/doi/pdf/10.1177/1352458517751049). The groups identified 10 key questions, and issued a series of recommendations based on the level of evidence. The following is a summary of the groups’ recommendations. Therapeutic intervention 1- All DMDs should be prescribed only in centres with adequate infrastructure to provide proper patient monitoring, comprehensive assessment,…